Clinical Trial: Fractional Laser as Treatment Option for Various Pigment Disorders

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Ablative Fractional Laser Therapy as Treatment for Becker's Nevus; a Pilot Study

Brief Summary: The purpose of this study is to determine whether the use of ablative fractional laser is effective in the treatment of Becker's nevus.

Detailed Summary: Becker's nevus (BN) is an uncommon pigment disorder of the epidermis characterized by increased pigmentation, a slightly elevated, verrucous surface of the affected skin and sometimes hyperpigmentation. No effective treatment is available. Several laser modalities have been applied in the treatment of Becker's nevus in uncontrolled studies with varying results. Recently, fractional laser therapy was suggested as treatment option for Becker's nevus. In fractional laser therapy, microscopic columns of skin are coagulated or ablated, leaving the surrounding tissue intact, which enhances healing of the treated skin. In this study, the efficacy and safety of ablative fractional laser therapy was assessed in the treatment of Becker's nevus.
Sponsor: Netherlands Institute for Pigment Disorders

Current Primary Outcome: Physician's global assessment [ Time Frame: T0, 3 and 6 months follow-up ]

Improvement of hyperpigmentation was assessed by an independent blinded dermatologist. The results were scored on a scale from zero to six (0: total clearance (100% improvement), 1: almost total clearance (90-99% improvement), 2: distinct clearance (75-89% improvement) 3: moderate clearance (50-74% improvement) 4: mild clearance (25-49% improvement) 5: no change, 6: worsening of hyperpigmentation).


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • L-value [ Time Frame: T0, 3 and six months follow-up ]
    Improvement of hyperpigmentation was assessed by color measurement through reflectance spectroscopy (Microflash 200 d, Datacolor International, Lawrenceville, GA). This instrument, with an aperture of 4 mm, determines color by measuring the intensity of reflected light of particular wavelengths. In this study, the obtained L value, reflecting the lightness of the measured area of skin, was used.
  • Melanin index [ Time Frame: T0, 3 and 6 months follow-up ]
    Melanin index was measured using a spectrometer (Derma-Spectrometer, Cortex Technology ApS, Hadsund, Denmark) in order to assess changes in the amount of dermal and epidermal melanin.
  • Patient's global assessment [ Time Frame: 3 and 6 months follow-up ]
    Patients were asked to score the improvement of hyperpigmentation on a visual analogue scale (VAS) from 0 to 10 (Patient's Global Assessment, PGA) at all follow-up moments.
  • Patient's satisfaction [ Time Frame: 3 and 6 months follow-up ]
    Patient's satisfaction was scored on a visual analogue scale (VAS) from 0 to 10.
  • Histopathologic assessment [ Time Frame: 3 months follow-up ]
    In order to evaluate for microscopic and ultrastructural treatment induced changes, 2 mm punch biopsies were taken from all patients at three months follow-up. Biopsies were taken from the optical centre of both treated and control site. All biopsy specimens were split for processing for light microscopy. .... was assessed by an independent blinded pathologist.


Original Secondary Outcome: Same as current

Information By: Netherlands Institute for Pigment Disorders

Dates:
Date Received: March 8, 2010
Date Started: March 2009
Date Completion:
Last Updated: March 8, 2010
Last Verified: March 2010